Retreatment with Alimta Leads to 4+ Year Survival for Peritoneal Mesothelioma Patient

geriatrics

There is new evidence that re-treatment with Alimta (pemetrexed) can significantly prolong survival for people with peritoneal mesothelioma, even after their cancer has come back. Cancer researchers in Zagreb, Croatia recently published the case report of a 45-year-old patient who lived for more than four years after a diagnosis of advanced peritoneal mesothelioma. His doctors credit his survival to cytoreductive surgery, intraperitoneal chemotherapy, and several rounds of systemic chemotherapy with Alimta after he relapsed. Treating Peritoneal Mesothelioma Peritoneal mesothelioma is a rare subtype of mesothelioma that affects the membrane surrounding the abdominal organs. Because it accounts for only a fifth of annual cases of the asbestos cancer, peritoneal mesothelioma has been studied even less than the more common pleural mesothelioma. … Continue reading Retreatment with Alimta Leads to 4+ Year Survival for Peritoneal Mesothelioma Patient »

Get your free copy of
“Surviving Mesothelioma” Today!